Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma

Aplidin ® is an antitumour drug, currently undergoing phase II evaluation in different haematological and solid tumours. In this study, we analysed the antimyeloma effects of Aplidin in the syngeneic 5T33MM model, which is representable for the human disease. In vitro , Aplidin inhibited 5T33MMvv DN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2008-06, Vol.98 (12), p.1966-1974
Hauptverfasser:	Caers, J, Menu, E, De Raeve, H, Lepage, D, Van Valckenborgh, E, Van Camp, B, Alvarez, E, Vanderkerken, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Biological and medical sciences Biomedical and Life Sciences Biomedicine Blotting, Western Bone marrow Cancer Research Cell Cycle Cells Cytotoxicity Depsipeptides - pharmacology Depsipeptides - therapeutic use Disease Models, Animal DNA Replication - drug effects Drug Resistance Epidemiology Hematology Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Laboratory animals Leukemia Medical research Medical sciences Mice Mice, Inbred C57BL Molecular Medicine Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Oncology Peptides, Cyclic Rats Translational Therapeutics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!